## **REMARKS**

Reconsideration of this application is requested in view of the proposed amendments to the claims and the remarks presented herein. Entry of the amendment is requested under the provisions of Rule 116 as it put the application in condition for allowance or in better condition for appeal.

The claims in the application are claims 6 to 10 and 14, all other claims having been cancelled.

All of the claims were rejected under 35 USC 112, first paragraph as being based on an enabling disclosure only for the monomer protein comprising an amino acid sequence of SEQ ID No: 2. The Examiner objected to claim 13 as being not enabled so as to be related to a MP52 protein wherein the cysteine related a dimer formation has been replaced by another amino acid. Claims 6 to 10 and 13 were also rejected under 35 USC 112, first paragraph, as being drawn to new matter. Claim 14 has not been rejected but was deemed to be drawn to allowable subject matter.

Applicants respectfully traverse these grounds of rejection in view of the amendments to the claims. Claim 13 has been cancelled and claim 14 has been rewritten in independent form as suggested by the Examiner. In addition, claims 6 to 10 are now dependent upon claim 14 which is drawn to allowable subject matter. Therefore, these claims are deemed to be drawn to allowable subject matter.

In view of the proposed amendments to the claims and the above remarks, it is believed that the claims clearly point out Applicants' patentable contribution and favorable reconsideration of the application is requested.

Respectfully submitted, Muserlian, Lucas and Mercanti

Charles A. Muserlian, 19,683

Attorney for Applicants Tel. # (212) 661-8000

CAM:ds Enclosure